Amneal Pharmaceuticals (AMRX) said Wednesday that it will launch mesalamine 800 milligram delayed-release tablets to treat moderately active ulcerative colitis in adults.
The company also said it has received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.
Amneal said that, in settlement of all product-related claims, Celgene has agreed to grant Amneal a license to Celgene's patents required to manufacture and sell generic lenalidomide in the US starting Jan. 31, 2026.
Amneal shares were up less than 1% in recent Wednesday premarket activity.
Price: 7.86, Change: +0.07, Percent Change: +0.9
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.